MHMark T. Heise

Mark T. Heise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark T. Heise has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Abdullah I. Al-Homoudi

    Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA

    1 shared publication
  • Hariprasad Aruri

    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA

    1 shared publication
  • Jacob Tartamella

    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA

    1 shared publication
  • Ladislau C. Kovari

    Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    1 shared publication
  • Narva Deshwar Kushwaha

    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201, USA

    1 shared publication
  • Nathaniel Moorman

    Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA

    1 shared publication

Latest Publications

  • Open Access

    Structure-Guided Design of Potent and Selective Covalent Inhibitors of SARS-CoV-1 and SARS-CoV-2 Papain-like Proteases with Antiviral Activity.

    by Abdullah I. Al-Homoudi, Narva Deshwar Kushwaha, Hariprasad Aruri, Jacob Tartamella, Nathaniel Moorman, Mark T. Heise, Ladislau Kovari, Navnath S. Gavande

    The papain-like protease (PLpro), one of two essential cysteine proteases in human coronaviruses, is indispensable for viral polyprotein processing and immune evasion through deubiquitination and deIS-Gylation of host proteins. This dual role makes PLpro an attractive antiviral target, either as a monother-apy or in combination with other direct-acting antivirals. Guided by structural insights, we designed and synthesized covalent inhibitors that exploit two key binding elements: Glu167 in the α-cleft (Site I), which mediates recognition of ubiquitin and ISG15, and the BL2 hydrophobic groove, which stabilizes inhibitor binding and shapes selectivity. The optimized inhibitors exhibited potent enzymatic inhibition (IC₅₀ = 25-100 nM), strong protein stabilization (ΔTₘ > 20 °C), and submicromolar antiviral activity in SARS-CoV-2–infected A549-ACE2 cells (EC₅₀ = 130-350 nM), with no measurable cytotoxicity (CC₅₀ > 10 µM). Lead compounds 8 (GL-612), 67 (GL-508), and 10 (GL-637) efficiently inactivated PLpro, with GL-637 achieving a kinact/KI > 18,000 M⁻¹ s⁻¹, and demonstrated selectivity by sparing host deubiquitinases USP7 and USP14 at concentrations up to 30 µM. Docking and mechanistic analyses revealed that cyclic amine-substituted benzamides reinforced electrostatic interactions with Glu167, while the (S)-3-fluoropyrrolidin-1-methyl-phenylthiophene scaffold anchored the BL2 groove, disrupting recognition of ubiquitin and ISG15 substrates. This dual engagement strategy improved covalent efficiency, strength-ened binding affinity, and translated into superior antiviral potency compared with benchmark compound 4. Collectively, these findings identify GL-612, GL-508, and GL-637 as first-in-class covalent PLpro in-hibitors that uniquely combine Glu167 engagement with BL2 groove occupancy, providing a strong foundation for broad-spectrum coronavirus therapeutic against current and emerging coronaviruses.